The United States represents a significant share of the Choroidal Neovascularization Market, driven by the high prevalence of age-related macular degeneration (AMD) and other retinal disorders among its growing elderly population. The country's advanced healthcare infrastructure, strong reimbursement policies, and widespread adoption of anti-VEGF therapies support market expansion. Furthermore, the presence of leading ophthalmology drug manufacturers and ongoing clinical research initiatives continue to accelerate innovation in CNV treatment.

The global Choroidal Neovascularization Market size is projected to reach US$ 12.81 billion by 2034 from US$ 7.29 billion in 2025. The market is anticipated to register a CAGR of 6.47% during the forecast period from 2026 to 2034. Choroidal neovascularization (CNV) is a severe ocular condition characterized by the growth of abnormal blood vessels beneath the retina, often leading to vision impairment and blindness if left untreated. The increasing incidence of retinal diseases, growing geriatric population, and continuous advancements in ophthalmology therapeutics are creating favorable conditions for market expansion worldwide. Pharmaceutical companies are focusing on developing long-acting therapies and novel treatment approaches to improve patient outcomes and reduce treatment burden.

Download Sample PDF Report: https://www.theinsightpartners.com/sample/TIPRE00016865

Market Drivers Fueling Growth

One of the primary drivers of the Choroidal Neovascularization Market is the rising prevalence of age-related macular degeneration (AMD), which remains one of the leading causes of vision loss among older adults globally. As life expectancy increases across developed and emerging economies, the number of individuals at risk of developing AMD and related retinal disorders continues to rise. This demographic trend is expected to generate sustained demand for effective CNV treatment options throughout the forecast period.

Another significant growth driver is the increasing adoption of anti-VEGF therapies. Anti-VEGF drugs have revolutionized the treatment landscape for CNV by effectively inhibiting abnormal blood vessel growth and preserving vision. Continuous innovations in drug formulations, extended-release therapies, and improved delivery systems are enabling better treatment outcomes and enhancing patient compliance. These advancements are encouraging healthcare providers to adopt advanced therapeutic options, thereby driving market growth.

The growing availability of advanced diagnostic technologies is also contributing significantly to market expansion. Optical coherence tomography (OCT), fluorescein angiography, and other sophisticated retinal imaging techniques facilitate early diagnosis and timely intervention. Early detection improves treatment effectiveness and reduces the risk of severe vision loss, encouraging healthcare systems worldwide to invest in modern ophthalmic diagnostic infrastructure.

Increasing Healthcare Expenditure and Research Investments

Rising healthcare expenditure across both developed and developing countries is supporting greater access to ophthalmic care services. Governments and healthcare organizations are increasingly recognizing the socioeconomic burden associated with vision impairment and blindness. As a result, significant investments are being directed toward eye care programs, screening initiatives, and treatment accessibility, creating favorable opportunities for market participants.

Research and development activities are also accelerating innovation within the market. Pharmaceutical companies and academic institutions are actively exploring next-generation therapies, including gene therapies, combination treatments, and sustained-release drug delivery systems. These innovations aim to reduce treatment frequency while maintaining therapeutic efficacy, thereby addressing key challenges associated with current treatment protocols.

Technological Advancements Transforming Treatment Landscape

Technological progress in ophthalmology continues to reshape the CNV treatment ecosystem. The integration of artificial intelligence (AI) into retinal imaging and disease detection is enhancing diagnostic accuracy and enabling earlier intervention. AI-powered diagnostic platforms assist clinicians in identifying subtle retinal changes, improving treatment planning and patient monitoring.

In addition, the development of longer-lasting anti-VEGF agents is reducing the frequency of intravitreal injections required by patients. Such advancements not only improve patient convenience but also reduce healthcare costs and resource utilization. The emergence of personalized medicine approaches is further expected to optimize treatment outcomes and support market growth over the coming years.

Emerging Markets Present Significant Opportunities

Emerging economies across Asia Pacific, Latin America, and the Middle East are becoming increasingly important contributors to market growth. Improvements in healthcare infrastructure, expanding access to specialized ophthalmic services, and growing awareness regarding retinal diseases are creating new opportunities for market participants. Furthermore, increasing healthcare spending and government-led vision care initiatives are expected to drive demand for CNV treatments in these regions.

The growing burden of diabetes and associated retinal complications is also contributing to increased demand for effective retinal disease management solutions. As awareness and diagnosis rates improve, a larger patient pool is expected to seek advanced treatment options, supporting sustained market expansion.

Competitive Landscape and Key Market Players

The Choroidal Neovascularization Market is characterized by intense competition and continuous innovation. Leading companies are focusing on strategic collaborations, product launches, clinical trials, and acquisitions to strengthen their market presence and expand their therapeutic portfolios.

Top Players in the Choroidal Neovascularization Market

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• AbbVie Inc.
• Pfizer Inc.
• Bausch + Lomb Corporation
• Santen Pharmaceutical Co., Ltd.
• Kodiak Sciences Inc.
• Adverum Biotechnologies, Inc.

These companies are actively investing in research and development to introduce innovative therapies and gain competitive advantages in the evolving ophthalmology market.

Future Outlook

The future of the Choroidal Neovascularization Market remains highly promising, driven by the increasing prevalence of retinal disorders, growing elderly population, technological advancements, and continuous innovation in anti-VEGF therapies. As healthcare systems prioritize early diagnosis and effective disease management, demand for advanced CNV treatment solutions is expected to rise steadily. The development of long-acting therapeutics, AI-enabled diagnostics, and personalized treatment strategies will further contribute to market growth through 2034.

About Us

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us

Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish